查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423570

2030年全球乳癌药物市场预测：依癌症类型、通路、最终用户和地区进行分析

Breast Cancer Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球乳癌药物市场规模为 291 亿美元，预计预测期内复合年增长率为 9.3%，到 2030 年将达到 543 亿美元。

乳癌药物是指各种旨在控制、治疗和治癒乳癌的治疗和介入措施。这些治疗方法包括多种方法，包括手术、化疗、放射线治疗、标靶治疗、荷尔蒙治疗、免疫治疗以及精准医学和基因治疗等新型治疗方法。治疗方法通常会根据癌症的阶段、其独特特征以及患者个体的健康状况和偏好而有所不同。

根据乳癌组织的统计数据，截至 2022 年 1 月，乳癌影响了超过 380 万名美国女性。根据此统计，预计到2022年，女性新诊断癌症中约30%将是乳癌。

乳癌发生率上升

全球乳癌发生率不断上升，推动了对治疗方案的更大需求，并刺激了研究和开发。新技术提供更有针对性的治疗方法，提高疗效并减少副作用。人们对早期检测的认识不断提高，强调了对综合治疗解决方案的需求，并为市场扩张创造了环境。需求的激增推动了竞争激烈的市场竞争策略，促进了加强患者照护的合作，并推动了市场向前发展。

治疗药物的副作用

乳癌治疗（例如标靶治疗）产生的副作用可能会限制市场成长。对于严重的副作用，患者可能不再能够使用该特定药物，并且可能必须转向其他类型的治疗。治疗的副作用可能很严重并影响患者的生活品质。

老年人口的扩大

世界人口老化正在增加癌症（包括乳癌）的发生率，对治疗方案的需求也在增加。年龄较大是乳癌的主要危险因素，因此不断增长的老年人口正在扩大潜在的患者群体。此外，该群体意识的提高和筛检方法的改进为早期发现和早期疗育提供了机会，从而促进更好的治疗结果和市场扩张。

昂贵的治疗费用

许多晚期乳癌治疗费用昂贵，限制了保险不足或无力负担的患者的治疗机会。经济挑战导致创新药物获取机会不平等，影响治疗效果和病患治疗结果。高成本也会为医疗保健系统带来负担，限制资源，并限制新的、更容易取得的治疗方法的研发。这些成本障碍阻碍了市场的成长。

COVID-19 的影响：

冠状病毒的爆发扰乱了全球经济，造成经济负担和经济逆境。许多行业，包括医疗保健行业，都见证了巨大的转变。优先考虑感染 COVID-19 的患者住院，并推迟其他医疗程序。疫情对全球市场的影响有限。

预计预测期内标靶治疗领域规模最大

预计标靶治疗细分市场将成为预测期内最大的细分市场。乳癌的标靶治疗透过攻击对癌症生长重要的特定分子，同时不伤害健康细胞，提供精确的治疗。与传统治疗方法相比，它透过减少副作用和提高疗效来改善患者的治疗结果。它透过找出不同途径来预防癌症进展的能力有望增强治疗效果、提高存活率并改善患者的生活品质。

预计医院药房行业在预测期内的复合年增长率最高。

预计医院药房领域在预测期内的复合年增长率最高。医院药局透过确保及时获得专门药物、优化药物治疗方案和提供个人化护理，在乳癌治疗中发挥着至关重要的作用。医院药局透过促进医疗团队之间的无缝协作并确保准确的药物管理和治疗监控来改善患者的治疗效果。

比最大的地区

由于政府的倡议和主要製药公司的存在，预计北美在预测期内将占据最大的市场占有率。该地区充满活力，不断进行研究、临床试验以及製药公司和研究机构之间的合作，推动创新。该地区还拥有强大的医疗基础设施和优惠的报销政策的支持，为患者提供先进的治疗。

复合年增长率最高的地区：

由于意识提高、技术进步和医疗设施普及等多种因素，预计亚太地区在预测期内将维持最高的复合年增长率。个人化医疗的趋势也在不断增长，它根据肿瘤的特异性特征调整趋势。采用先进的诊断工具和治疗方法显着改善了患者的治疗效果。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球乳癌治疗市场：依治疗方法

  • 荷尔蒙治疗
    • Aromatase酶抑制剂
    • 雌激素受体下稳压器(ERD)
    • 选择性雌激素受体调节剂 (SERM)
  • 标靶治疗
    • 曲妥珠单抗
    • 帕妥珠单抗
    • Everolimus
    • 阿多曲妥珠单抗emtansine
    • Palbociclib
    • 瑞博西尼
    • 奥拉帕尼
    • Abemaciclib
  • 化疗
  • 免疫疗法
  • 其他治疗方法

第六章全球乳癌治疗市场：依癌症类型分类

  • HER2+
  • 荷尔蒙受体

第七章全球乳癌治疗市场：依通路划分

  • 零售药房
  • 医院药房
  • 网路药房

第八章全球乳癌治疗市场：依最终用户分类

  • 调查机构
  • 诊断中心
  • 诊所
  • 其他最终用户

第九章全球乳癌治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Perkin Elmer Inc.
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • NanoString Technologies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb
  • Clovis Oncology
Product Code: SMRC24804

According to Stratistics MRC, the Global Breast Cancer Therapeutics Market is accounted for $29.1 billion in 2023 and is expected to reach $54.3 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Breast cancer therapeutics refers to the various treatments and interventions designed to manage, treat, or cure breast cancer. These therapeutics encompass a wide range of approaches, including surgery, chemotherapy, radiation therapy, targeted therapy, hormone therapy, immunotherapy, and newer emerging treatments like precision medicine and gene therapy. Therapeutic approaches often vary based on the stage of the cancer, its specific characteristics, and the individual patient's health and preferences.

According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The increasing prevalence of breast cancer globally prompts greater demand for therapeutic options, spurring research and development efforts. Emerging technologies offer more targeted therapies, improving efficacy and reducing side effects. The growing awareness of early detection emphasizes the need for comprehensive treatment solutions, creating a conducive environment for market expansion. This surge in demand encourages competitive pricing strategies and fosters collaborations for enhanced patient care, propelling the market forward.

Restraint:

Adverse effects of therapeutics

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. Side effects of treatments can be severe and impact the patient's quality of life.

Opportunity:

Expanding geriatric population

With an aging population worldwide, there's a higher incidence of cancer, including breast cancer, leading to a greater demand for therapeutic options. With advanced age being a primary risk factor for breast cancer, the growing demographic of older individuals creates a larger pool of potential patients. Additionally, increased awareness and improved screening methods within this population offer opportunities for early detection and intervention, fostering better treatment outcomes and market expansion.

Threat:

High cost of therapies

Many advanced breast cancer treatments are expensive, limiting access for patients without adequate insurance coverage or financial resources. Affordability issues lead to unequal access to innovative medications, impacting treatment efficacy and patient outcomes. High expenses also burden healthcare systems, constraining resources and potentially limiting research and development of newer, more accessible therapies. These cost barriers hinder the growth of the market.

Covid-19 Impact:

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. The pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients.

The targeted therapy segment is expected to be the largest during the forecast period

The targeted therapy segment is expected to be the largest during the forecast period. Targeted therapy in breast cancer offers precise treatment, attacking specific molecules crucial for cancer growth while sparing healthy cells. It enhances efficacy with reduced side effects compared to traditional treatments, improving patient outcomes. Their ability to prevent cancer's progression by pinpointing distinct pathways amplifies treatment effectiveness, promising better survival rates and a higher quality of life for patients.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies play a pivotal role in breast cancer therapeutics by ensuring timely access to specialized medications, optimizing drug regimens, and providing personalized care. They facilitate seamless coordination between healthcare teams, ensuring accurate dosing and monitoring of treatments, thereby enhancing patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to government initiatives, and the presence of key pharmaceutical companies. The region is dynamic, with ongoing research, clinical trials, and collaborations between pharmaceutical companies and research institutions driving innovation. It's also supported by strong healthcare infrastructure and favorable reimbursement policies, allowing patients access to advanced treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors, including increasing awareness, advancements in technology and improved access to healthcare facilities. There's also a growing trend toward personalized medicine, where treatments are tailored based on the specific characteristics of the tumor. The adoption of advanced diagnostic tools and treatment modalities has significantly improved patient outcomes.

Key players in the market

Some of the key players in Breast Cancer Therapeutics market include Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, Perkin Elmer Inc., Pfizer Inc., Puma Biotechnology Inc., NanoString Technologies Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Clovis Oncology.

Key Developments:

In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.

In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.

Therapies Covered:

  • Hormonal Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Other Therapies

Cancer Types Covered:

  • HER2+
  • Hormone Receptor

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

End Users Covered:

  • Research Institutions
  • Diagnostic Centers
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Therapeutics Market, By Therapy

  • 5.1 Introduction
  • 5.2 Hormonal Therapy
    • 5.2.1 Aromatase Inhibitors
    • 5.2.2 Estrogen Receptor Downregulators (ERDs)
    • 5.2.3 Selective Estrogen Receptor Modulators (SERMs)
  • 5.3 Targeted Therapy
    • 5.3.1 Trastuzumab
    • 5.3.2 Pertuzumab
    • 5.3.3 Everolimus
    • 5.3.4 Ado-Trastuzumab Emtansine
    • 5.3.5 Palbociclib
    • 5.3.6 Ribociclib
    • 5.3.7 Olaparib
    • 5.3.8 Abemaciclib
  • 5.4 Chemotherapy
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Breast Cancer Therapeutics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 HER2+
  • 6.3 Hormone Receptor

7 Global Breast Cancer Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies

8 Global Breast Cancer Therapeutics Market, By End User

  • 8.1 Introduction
  • 8.2 Research Institutions
  • 8.3 Diagnostic Centers
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Breast Cancer Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Exelixis Inc.
  • 11.2 F. Hoffmann La Roche Ltd.
  • 11.3 GlaxoSmithKline Plc
  • 11.4 Merck and Co. Inc.
  • 11.5 Sanofi
  • 11.6 Teva Pharmaceutical Industries Ltd.
  • 11.7 Viatris Inc.
  • 11.8 Novartis AG
  • 11.9 Perkin Elmer Inc.
  • 11.10 Pfizer Inc.
  • 11.11 Puma Biotechnology Inc.
  • 11.12 NanoString Technologies Inc.
  • 11.13 Daiichi Sankyo Co. Ltd.
  • 11.14 Eisai Co. Ltd.
  • 11.15 Eli Lilly and Co.
  • 11.16 AbbVie Inc.
  • 11.17 Amgen Inc.
  • 11.18 Bristol Myers Squibb
  • 11.19 Clovis Oncology

List of Tables

  • Table 1 Global Breast Cancer Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Breast Cancer Therapeutics Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 3 Global Breast Cancer Therapeutics Market Outlook, By Hormonal Therapy (2021-2030) ($MN)
  • Table 4 Global Breast Cancer Therapeutics Market Outlook, By Aromatase Inhibitors (2021-2030) ($MN)
  • Table 5 Global Breast Cancer Therapeutics Market Outlook, By Estrogen Receptor Downregulators (ERDs) (2021-2030) ($MN)
  • Table 6 Global Breast Cancer Therapeutics Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2021-2030) ($MN)
  • Table 7 Global Breast Cancer Therapeutics Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 8 Global Breast Cancer Therapeutics Market Outlook, By Trastuzumab (2021-2030) ($MN)
  • Table 9 Global Breast Cancer Therapeutics Market Outlook, By Pertuzumab (2021-2030) ($MN)
  • Table 10 Global Breast Cancer Therapeutics Market Outlook, By Everolimus (2021-2030) ($MN)
  • Table 11 Global Breast Cancer Therapeutics Market Outlook, By Ado-Trastuzumab Emtansine (2021-2030) ($MN)
  • Table 12 Global Breast Cancer Therapeutics Market Outlook, By Palbociclib (2021-2030) ($MN)
  • Table 13 Global Breast Cancer Therapeutics Market Outlook, By Ribociclib (2021-2030) ($MN)
  • Table 14 Global Breast Cancer Therapeutics Market Outlook, By Olaparib (2021-2030) ($MN)
  • Table 15 Global Breast Cancer Therapeutics Market Outlook, By Abemaciclib (2021-2030) ($MN)
  • Table 16 Global Breast Cancer Therapeutics Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 17 Global Breast Cancer Therapeutics Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 18 Global Breast Cancer Therapeutics Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 19 Global Breast Cancer Therapeutics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 20 Global Breast Cancer Therapeutics Market Outlook, By HER2+ (2021-2030) ($MN)
  • Table 21 Global Breast Cancer Therapeutics Market Outlook, By Hormone Receptor (2021-2030) ($MN)
  • Table 22 Global Breast Cancer Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Breast Cancer Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Breast Cancer Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 25 Global Breast Cancer Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 Global Breast Cancer Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Breast Cancer Therapeutics Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 28 Global Breast Cancer Therapeutics Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 29 Global Breast Cancer Therapeutics Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 30 Global Breast Cancer Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.